Anzeige
Mehr »
Donnerstag, 16.10.2025 - Börsentäglich über 12.000 News
Jetzt folgt der nächste Coup - CiTech mit Lettland jetzt auf Europas Verteidigungsbühne
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PN04 | ISIN: CA05368K1003 | Ticker-Symbol: 0NN
Frankfurt
16.10.25 | 08:05
0,173 Euro
+12,34 % +0,019
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AVICANNA INC Chart 1 Jahr
5-Tage-Chart
AVICANNA INC 5-Tage-Chart

Aktuelle News zur AVICANNA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.09.Avicanna Inc: Avicanna appoints Hilborn as interim CFO1
13.09.Avicanna Inc.: Avicanna Announces Change in CFO553TORONTO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing...
► Artikel lesen
AVICANNA Aktie jetzt für 0€ handeln
04.09.Avicanna Inc: Avicanna exports cannabis flower to Switzerland2
03.09.Stocks in Play: Avicanna Inc.4
03.09.Avicanna Inc.: Avicanna Subsidiary Completes Export of CBD Dominant Cannabis Flower into Switzerland124This marks the first export of organic certified flower for SMGH, 20th international market for Aureus branded products and 23rd market for all Avicanna products TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE)...
► Artikel lesen
03.09.Avicanna Inc: Avicanna Latam launches re+PLAY CBD wellness brand1
02.09.Avicanna Inc.: Avicanna LATAM SAS Teams Up With Harrington Wellness to Launch re+PLAY CBD Wellness Brand Topicals in the United States6
14.08.Avicanna reports Q2 results2
14.08.Avicanna Inc.: Avicanna Reports Q2 2025330TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
► Artikel lesen
11.08.Avicanna Inc: Avicanna receives U.S. patent2
11.08.Avicanna Inc.: Avicanna Announces US Patent and Trademark Office Issuance of New Patent2
17.07.Avicanna Inc: Avicanna closes $1-million private placement3
16.07.Avicanna Inc.: Avicanna Announces Closing of Non-Brokered Private Placement14
01.07.Avicanna Inc: Avicanna shareholders approve AGM resolutions1
30.06.Avicanna Inc.: Avicanna Announces Results of Annual General Meeting519TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
► Artikel lesen
20.05.Avicanna Inc.: Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain321TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and...
► Artikel lesen
15.05.Stocks in Play: Avicanna Inc.11
15.05.Avicanna Inc.: Avicanna Reports Q1 2025 Results and First Profitable Quarter263TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
► Artikel lesen
16.04.Avicanna Inc.: Avicanna Announces Revocation of Management Cease Trade Order191TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and...
► Artikel lesen
14.04.Avicanna Inc.: Avicanna Reports Full Year 2024 Audited Financial Statement2642024 Revenue of $25.5M, a 52% increase from 2023 Consolidated Gross Margins of 51%, Gross Profits of $12.9M, a 94% increase from 2023 TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna"...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1